» Articles » PMID: 37989490

Isolated Small Airways Obstruction Predicts Future Chronic Airflow Obstruction: a Multinational Longitudinal Study

Abstract

Background: Chronic airflow obstruction is a key characteristic of chronic obstructive pulmonary disease. We investigated whether isolated small airways obstruction is associated with chronic airflow obstruction later in life.

Methods: We used longitudinal data from 3957 participants of the multinational Burden of Obstructive Lung Disease study. We defined isolated small airways obstruction using the prebronchodilator mean forced expiratory flow rate between 25% and 75% of the forced vital capacity (FVC) (FEF) if a result was less than the lower limit of normal (<LLN) in the presence of a normal forced expiratory volume in 1 s to FVC ratio (FEV/FVC). We also used the forced expiratory volume in 3 s to FVC ratio (FEV/FVC) to define small airways obstruction. We defined chronic airflow obstruction as post-bronchodilator FEV/FVC<LLN. We performed mixed effects regression analyses to model the association between baseline isolated small airways obstruction and chronic airflow obstruction at follow-up. We assessed discriminative and predictive ability by calculating the area under the receiver operating curve (AUC) and Brier score. We replicated our analyses in 26 512 participants of the UK Biobank study.

Results: Median follow-up time was 8.3 years. Chronic airflow obstruction was more likely to develop in participants with isolated small airways obstruction at baseline (FEF less than the LLN, OR: 2.95, 95% CI 1.02 to 8.54; FEV/FVC less than the LLN, OR: 1.94, 95% CI 1.05 to 3.62). FEF was better than the FEV/FVC ratio to discriminate future chronic airflow obstruction (AUC: 0.764 vs 0.692). Results were similar among participants of the UK Biobank study.

Conclusion: Measurements of small airways obstruction can be used as early markers of future obstructive lung disease.

Citing Articles

Optimal spirometry thresholds for the prediction of chronic airflow obstruction: a multinational longitudinal study.

Lam A, Alhajri S, Potts J, Harrabi I, Anand M, Janson C ERJ Open Res. 2025; 11(2).

PMID: 40040898 PMC: 11873882. DOI: 10.1183/23120541.00624-2024.


New spirometry recommendations from the Brazilian Thoracic Association - 2024 update.

Albuquerque A, Berton D, Campos E, Queiroga-Junior F, Santana A, Wong B J Bras Pneumol. 2025; 50(6):e20240169.

PMID: 39841775 PMC: 11796395. DOI: 10.36416/1806-3756/e20240169.


Identification of factors directly linked to incident chronic obstructive pulmonary disease: A causal graph modeling study.

Gregg R, Karoleski C, Silverman E, Sciurba F, DeMeo D, Benos P PLoS Med. 2024; 21(8):e1004444.

PMID: 39137208 PMC: 11349214. DOI: 10.1371/journal.pmed.1004444.


Postbronchodilator Spirometry Reference Values Are Needed and Helpful for Identifying Pre-Chronic Obstructive Pulmonary Disease.

Malinovschi A, Johannessen A Am J Respir Crit Care Med. 2024; 210(7):857-859.

PMID: 39093573 PMC: 11506898. DOI: 10.1164/rccm.202406-1212ED.


Mortality risk associated with occupational exposures in people with small airways obstruction.

Quintero-Santofimio V, Minelli C, Potts J, Vermeulen R, Kromhout H, Knox-Brown B PLoS One. 2024; 19(6):e0305125.

PMID: 38861560 PMC: 11166274. DOI: 10.1371/journal.pone.0305125.


References
1.
Feary J, Quintero-Santofimio V, Potts J, Vermeulen R, Kromhout H, Knox-Brown B . Occupational exposures and small airway obstruction in the UK Biobank Cohort. ERJ Open Res. 2023; 9(3). PMC: 10204826. DOI: 10.1183/23120541.00650-2022. View

2.
. Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2020; 8(6):585-596. PMC: 7284317. DOI: 10.1016/S2213-2600(20)30105-3. View

3.
Tenin K, Aurelien S, Daniela M, Denis C, Frederic C . Prevalence of a decreased FEV3/FEV6 ratio in symptomatic smokers with preserved lung function. Respir Med Res. 2022; 81:100891. DOI: 10.1016/j.resmer.2022.100891. View

4.
Vestbo J, Hurd S, Agusti A, Jones P, Vogelmeier C, Anzueto A . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2012; 187(4):347-65. DOI: 10.1164/rccm.201204-0596PP. View

5.
Hansen J, Sun X, Wasserman K . Discriminating measures and normal values for expiratory obstruction. Chest. 2006; 129(2):369-377. DOI: 10.1378/chest.129.2.369. View